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Abstract
Background The recent AFFIRM-AHF trial assessing the effect of intravenous (IV) iron on outcomes in patients hospital-
ised with worsening heart failure who had iron deficiency (ID) narrowly missed its primary efficacy endpoint of recurrent 
hospitalisations for heart failure (HHF) or cardiovascular (CV) death. We conducted a meta-analysis to determine whether 
these results were consistent with previous trials.
Methods We searched for randomised trials of patients with heart failure investigating the effect of IV iron vs placebo/control 
groups that reported HHF and CV mortality from 1st January 2000 to 5th December 2020. Seven trials were identified and 
included in this analysis. A fixed effect model was applied to assess the effects of IV iron on the composite of first HHF or 
CV mortality and individual components of these.
Results Altogether, 2,166 patients were included (n = 1168 assigned to IV iron; n = 998 assigned to control). IV iron reduced 
the composite of HHF or CV mortality substantially [OR 0.73; (95% confidence interval 0.59–0.90); p = 0.003]. Outcomes 
were consistent for the pooled trials prior to AFFIRM-AHF. Whereas first HHF were reduced substantially [OR 0.67; 
(0.54–0.85); p = 0.0007], the effect on CV mortality was uncertain but appeared smaller [OR 0.89; (0.66–1.21); p = 0.47].
Conclusion Administration of IV iron to patients with heart failure and ID reduces the risk of the composite outcome of 
first heart failure hospitalisation or cardiovascular mortality, but this outcome may be driven predominantly by an effect on 
HHF. At least three more substantial trials of intravenous iron are underway.
Graphic abstract
Heart failure & iron deficiency
n = 2,166
Intravenous iron
n = 1,168 
Reduction in risk of hospitalisation for heart 
failure in subsequent 6-12 months by ~30%
In a meta-analysis of 7 trials, administration of IV iron to patients with heart failure and 
iron deficiency reduces the risk of the composite outcome of first heart failure 
hospitalisation or cardiovascular mortality, but this outcome is driven predominantly by an 
effect on heart failure hospitalisations.
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Introduction
Patients with heart failure often have evidence of iron defi-
ciency (ID), with or without anaemia, which is associated 
with more severe symptoms, lower exercise capacity and 
higher rates of hospitalisations for heart failure (HHF) and 
mortality [1, 2]. In an individual patient meta-analysis of 
four trials including 839 patients with heart failure with 
reduced ejection fraction (HFrEF) and serum markers of 
ID, Anker and colleagues suggested that administration of 
intravenous iron (IV) reduced the risk of first and recurrent 
HHF when compared to placebo [3]. Recently, the AFFIRM-
AHF trial narrowly missed its primary efficacy endpoint of 
recurrent HHF or cardiovascular (CV) death [4]. Therefore, 
we produced an updated the meta-analysis to investigate 
whether the effects of IV iron were consistent amongst the 
randomised trials reported so far and whether sufficient evi-
dence had accumulated to indicate a conclusive effect on 
HHF and CV mortality.
Methods
We searched for English language trials from 1st January 
2000 to 5th December 2020 in PubMed using pre-specified 
search terms (see Supplements), and from additional sources 
including a recent systematic review [5]. Only published ran-
domised trials investigating the effects of IV iron compared 
to a control group that did not receive IV iron in patients 
with heart failure, regardless of participants’ left ventricular 
ejection fraction, the formulation of IV iron, concomitant 
therapy, or definition of ID, that reported either HHF or CV 
mortality were included in the main report. If mortality was 
not explicitly reported but HHF was, it was assumed that 
no deaths had occurred. An additional analysis was done 
including two unpublished trials, with data derived from the 
meta-analysis reported by Anker et al. [3].
Data were extracted by two independent reviewers (FG 
and PP). Deaths not clearly declared as CV or non-CV were 
adjudicated independently by two authors, both of whom are 
experienced in clinical end-point adjudication. Adjudication 
was based on the clinical information provided by authors 
in the text. Disparities were resolved by discussion or by 
checking with a third author (JGFC). Outcomes assessed 
were the composite of HHF or CV mortality as first events, 
and HHF as a first event and CV mortality separately. Data 
analysed were the numbers of first events and numbers of 
participants in each treatment arm for each trial. Odds ratios 
and 95% confidence intervals for the effect of treatment with 
IV iron relative to control were calculated for each trial. 
The data were analysed using both fixed effects (primary 
analysis) and random effects models. Forest plots with odds 
ratios and corresponding (95% confidence intervals) were 
produced and reported. A level of significance of 5% was 
considered statistically significant.
To assess the impact of results from the largest trial to 
date, additional analysis comparing odds ratios for studies 
excluding AFFIRM-AHF to the AFFIRM-AHF trial alone 
were carried out.
All analyses were conducted with Review Manager (Rev-
Man) Version 5.4 (The Cochrane Collaboration, 2020).
Results
We identified 19 reports assessing the effect of iron therapy 
in patients with heart failure (Fig. 1). After excluding 12 
reports [6–17], mainly because they were not randomised-
controlled trials or did not report relevant outcomes (Supple-
mentary Table S1), seven trials (Table 1) that enrolled 2,166 
patients (n = 1168 assigned to IV iron; n = 998 assigned to 
the control/placebo) were included in the primary analysis 
[4, 18–23]. The most common definition of ID was a ferri-
tin < 100 µg/L and/or, if ferritin was 100–300 µg/L, a TSAT 
of < 20%. Most trials excluded patients with a very low 
haemoglobin (less than 8–10 g/dL) or with values greater 
than 15 g/dL [4, 19]. Only two trials followed patients 
for > 6 months [4, 19]. Five trials used ferric carboxymaltose 
and two used iron sucrose [21, 22].
In the primary analysis, IV iron reduced the compos-
ite outcome of HHF or CV death: OR 0.73 [0.59–0.90]; 
p = 0.003 (Fig. 2a). HHF occurred in 175 (15%) patients 
administered IV iron and 227 (23%) assigned to control: OR 
0.67 [0.54–0.85]; p = 0.0007 (Fig. 2b). CV deaths occurred 
in 93 (8%) patients administered IV iron and in 98 (10%) 
assigned to control: OR 0.89 [0.66–1.21]; p = 0.47 (Fig. 2c). 
Adding data from the two unpublished trials to the main 
analysis did not substantially alter these results (Supplemen-
tary Figure S1).
When AFFIRM-AHF was excluded from the model, 
the point estimates for the effect of IV iron were OR 0.59 
[0.39–0.89]; p = 0.01 for the composite outcome, OR 0.57 
[0.36–0.90]; p = 0.02 for HHF and OR 0.66 [0.34–1.28]; 
p = 0.22 for CV mortality (Table 2 and Fig. 3). The odds 
ratios for all outcomes were not significantly different for 
the pooled data excluding AFFIRM-AHF compared to 
AFFIRM-AHF alone (Table 3).
In random effects models, IV iron reduced the composite 
outcome [OR 0.74 (0.60–0.91); p = 0.005] but neither HHF 
Clinical Research in Cardiology 
1 3
[OR 0.64 (0.40–1.04); p = 0.07] nor CV mortality [OR 0.91 
(0.67–1.24); p = 0.56] (Supplementary Figure S2). Results 
were similar when AFFIRM-AHF was excluded (Table 2 
and Supplementary Figure S3).
Discussion
This meta-analysis suggests that IV iron reduces the risk of 
the composite outcome of first HHF or CV death for patients 
with serum markers of ID and heart failure. This result was 
driven predominantly by an effect on HHF with no con-
vincing evidence of a reduction in CV mortality. Because 
HHF is associated with a higher risk of CV mortality, the 
effect of IV iron for each outcome might be expected to be 
rather similar. The relatively small number of deaths, the 
short duration of follow-up and the play of chance might 
explain this possible anomaly. A longer duration of follow-
up might show a greater effect on CV mortality, but the 
trial with the longest follow-up to date, albeit only one year, 
showed little effect on this outcome [4]. The AFFIRM-AHF 
trial suggests that the reduction in hospitalisations for heart 
failure is not observed until 8–12 weeks after administra-
tion of IV iron, consistent with its benefits being mediated 
through the synthesis of new red blood cells, myoglobin and 
other metalloproteins. Accordingly, large effects observed 
in some small trials lasting 3 months or less may reflect 
chance effects.
The effects of IV iron appeared somewhat greater in a 
pooled analysis of trials excluding AFFIRM-AHF, although 
differences were not statistically significant. IV iron might 
be more effective in clinically stable populations. Differ-
ences in study design, inclusion criteria, iron dosing and 
length of follow-up may affect the outcome. The small size 
of some trials confounded statistical assessment of hetero-
geneity. Instead, we produced both fixed and random effects 
models which, for the composite outcome, yielded similar 
results, although less secure for effects on HHF in the ran-
dom effects model.
Whether the definition of ID used in these trials is opti-
mal is uncertain. Using a TSAT < 20% alone might be a bet-
ter guide to ID than one based on ferritin [24–26]. This is 
important because giving IV iron to patients who are not 
iron-deplete is unlikely to be beneficial. Fortunately, ID 
appears common in patients with heart failure and therefore 
an effect might be detected even if the diagnostic accuracy 
of the test for ID is poor. Perhaps most patients with heart 
failure have ID and the key question is how severe it is, 
rather than whether it is present; ID should not be a binary, 
all-or-nothing classification.
Fig. 1  PRISMA diagram 
detailing the number of records 
identified, screened, included, 
and excluded, with a summary 
of the reasons for exclusion. 
Modified from Moher D, Lib-
erati A, Tetzlaff J, Altman DG, 
The PRISMA Group (2009). 
Preferred Reporting Items 
for Systematic Reviews and 
Meta-Analyses: the PRISMA 
statement. PLoS Med 6(7): 
e1000097. 10.1371/journal.
pmed1000097. ID iron defi-
ciency, HHF hospitalisation for 
heart failure, CV cardiovascular
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Fig. 2  Fixed-effects meta-
analysis model of all included 
trials detailing the pooled effect 
of intravenous iron on the com-
posite of first hospitalisations 
for heart failure or cardiovas-
cular mortality (a), and first 
hospitalisation for heart failure 
(b) and cardiovascular mortality 
(c) alone. IV intravenous, CI 
confidence interval
Table 2  Summary of results 
from meta-analysis models, 
with and without AFFIRM-
AHF, and AFFIRM-AHF alone, 
assessing the effect of IV iron 
on outcomes
IV intravenous, OR odds ratio, CI confidence interval, CVM cardiovascular mortality, HHF hospitalisation 
for heart failure
Outcome IV iron Controls Fixed effect Random effect
Events Patients Events Patients OR (95% CI) p OR (95% CI) p
AFFIRM-AHF excluded
 CVM or HHF 46 610 63 448 0.59 (0.39, 0.89) 0.01 0.62 (0.41, 0.93) 0.02
 HHF 33 610 49 448 0.57 (0.36, 0.90) 0.02 0.60 (0.28, 1.28) 0.19
 CVM 16 610 20 448 0.66 (0.34, 1.28) 0.22 0.72 (0.36, 1.43) 0.35
AFFIRM-AHF
 CVM or HHF 181 558 209 550 0.78 (0.61, 1.00) – 0.78 (0.61, 1.00) –
 HHF 142 558 178 550 0.71 (0.55, 0.93) – 0.71 (0.55, 0.93) –
 CVM 77 558 78 550 0.97 (0.69, 1.36) – 0.97 (0.69, 1.36) –
All Trials
 CVM or HHF 227 1168 272 998 0.73 (0.59, 0.90) 0.003 0.74 (0.60–0.91) 0.005
 HHF 175 1168 227 998 0.67 (0.54, 0.85) 0.0007 0.64 (0.40, 1.04) 0.07
 CVM 93 1168 98 998 0.89 (0.66, 1.21) 0.47 0.91 (0.67, 1.24) 0.56
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We did not conduct subgroup analyses, which are best 
left to an individual-patient-data (IPD) meta-analysis that 
can adjust for confounding variables. In an IPD meta-anal-
ysis [3], lower TSAT but not lower serum ferritin predicted 
greater benefit from IV iron. In AFFIRM-AHF it appeared 
that lower serum ferritin or a lower TSAT were associated 
Fig. 3  Fixed-effects meta-analy-
sis model of all trials, excluding 
AFFIRM-AHF, detailing the 
pooled effect of intravenous 
iron on the composite of first 
hospitalisations for heart failure 
or cardiovascular mortality 
(a), and first hospitalisation for 
heart failure (b) and cardio-
vascular mortality (c) alone. 
Although not included in the 
pooled analysis, odds ratios and 
95% confidence intervals are 
presented for AFFIRM-AHF for 
comparison. IV intravenous, CI 
confidence interval
Table 3  Comparison of fixed-effects odds ratios (ORs) between pooled trials prior to AFFIRM-AHF and AFFIRM-AHF
Odds ratio (95% confidence interval) P for comparison OR (95% confidence interval) of comparison
Composite endpoint
 All trials except AFFIRM-AHF 0.59 (0.39, 0.89) 0.26 0.76 (0.47, 1.22)
 AFFIRM-AHF 0.78 (0.61, 1.00)
Hospitalisation for heart failure
 All trials except AFFIRM-AHF 0.57 (0.36, 0.90) 0.41 0.80 (0.47, 1.36)
 AFFIRM-AHF 0.71 (0.55, 0.93)
Cardiovascular mortality
 All trials except AFFIRM-AHF 0.66 (0.34, 1.28) 0.31 0.68 (0.32, 1.43)
 AFFIRM-AHF 0.97 (0.69, 1.36)
with greater benefit from IV iron, but > 80% of participants 
had a TSAT < 20%. Further analyses are required. Haemo-
globin concentration has not predicted benefit but, because 
women have lower concentrations than men, such analyses 
may be confounded by participants’ sex. The AFFIRM-
AHF trial enrolled patients with new-onset heart failure, 
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which is unusual for trials of heart failure; these patients 
may have had somewhat less benefit from IV iron possibly 
because they were less likely to have true ID or because 
the determinants of outcome in such patients are different. 
In AFFIRM-AHF patients with ischaemic cardiomyopathy 
appeared to have greater benefit; the reasons for this are 
unclear. The reduction in events with IV iron, compared to 
control, might have been underestimated because treatments 
for heart failure might have been more likely to be intensified 
in the control group who did not receive the symptomatic 
benefits of iron therapy. This possibility should be explored 
in the future analysis of substantial long-term trials.
Results from three other large ongoing trials should 
clarify the effects of IV iron on morbidity and mortality in 
patients with HFrEF and ID and provide further insights 
into the possible predictors of response [27]. Trials in heart 
failure with preserved ejection fraction are also underway 
but limited data currently exist [23].
Limitations
We did not investigate the effect of IV iron on all-cause mor-
tality as this is not yet reported for AFFIRM-AHF. The com-
posite outcome reported for CONFIRM-HF [19] was HHF 
and all-cause mortality, which included one non-CV death 
amongst patients assigned to iron and two to placebo. This 
would not materially alter our overall results. An analysis of 
recurrent HHF rather than just the first event would make the 
result more robust but requires access to IPD. An IPD meta-
analysis has many advantages when exploring the interaction 
amongst variables [28–30]. In particular, an IPD would have 
allowed analysis of the potential interaction between sex 
and the effects of IV iron. However, aggregate data have the 
advantage that it includes all the published data rather than 
the proportion where IPD is available to the authors. Each 
type of meta-analysis has advantages, and they are compli-
mentary. All meta-analyses should be interpreted cautiously, 
particularly for analyses involving a number of small stud-
ies where there will be little power to detect heterogeneity. 
Fixed effects meta-analysis provides an estimate of an aver-
age treatment effect in the studies conducted but uncertainty 
about heterogeneity may make it difficult to extrapolate that 
effect to a particular clinical context. Random effects analy-
ses assume that studies have underlying treatment effects 
arising from a random distribution and provide estimates of 
the average of, and variation in, the treatment effect in that 
distribution. However, if the variation is systematic and not 
random then the random effects analysis may not be helpful 
in extrapolating a treatment effect to a new situation. In the 
context of this analysis, length of follow-up, clinical status 
of patients at recruitment and IV iron dosing strategy are 
systematically different amongst the studies. Whether these 
factors systematically impact the treatment effect is difficult 
to determine with the data available.
Conclusion
In a meta-analysis of seven trials, administration of IV iron 
to patients with heart failure and ID reduced the risk of the 
composite outcome of heart failure hospitalisation or car-
diovascular mortality in the following 12 months. To date, 
this outcome is driven predominantly by an effect on HHF. 
Longer term effects of repeated administration of IV iron are 
unknown. More evidence is desirable.
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